Latest News

PDMR dealings

25 June 2019

New York/London, 25 June 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on 24 June 2019, Panetta Partners...

Read more

Newly Published Article Reporting Clinical Activity of Orally Administered OKT3, a Mouse Anti-CD3 Monoclonal Antibody, in Moderate to Severe Ulcerative Colitis Patients, Supports Tiziana’s Oral Monoclonal Antibody Platform

24 June 2019

-

Read more

PDMR Dealings

11 June 2019

New York/London, 11 June 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on 10 June 2019, Panetta Partners...

Read more

PDMR Dealings

07 June 2019

New York/London, 7 June 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on 5 June 2019, Panetta Partners...

Read more

PDMR dealings

03 June 2019

New York/London, 3 June 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on 31 May 2019, Panetta Partners...

Read more

Results of Annual General Meeting

31 May 2019

Tiziana announces that at the Annual General Meeting of the Company held at 10:00 a.m. on 31 May 2019 all the resolutions proposed were duly passed.

Read more

Page 1 of 5 Next